EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer

Natalia Gorbokon, Niklas Wößner, Viktoria Ahlburg, Henning Plage, Sebastian Hofbauer, Kira Furlano, Sarah Weinberger, Paul Giacomo Bruch, Simon Schallenberg, Florian Roßner, Sefer Elezkurtaj, Maximilian Lennartz und 19 weitere

The Journal of Pathology: Clinical Research · 2025

DOI: 10.1002/2056-4538.70012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2025. Verfasst von Natalia Gorbokon und 30 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Purine-Nucleoside Phosphorylase, Chromosomes, Human, Pair 9, Tumor Microenvironment. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Society of Urology, Deutsche Gesellschaft für Urologie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Homozygous 9p21 deletions usually result in a complete loss of S‐methyl‐5′‐thioadenosine phosphorylase (MTAP) expression visualizable by immunohistochemistry (IHC). MTAP deficiency has been proposed as a marker for predicting targeted treatment response. A tissue microarray including 2,710 urothelial bladder carcinomas were analyzed for 9p21 deletion by fluorescence in situ hybridization and MTAP expression by IHC. Data were compared with data on tumor phenotype, patient survival, intratumoral lymphocyte subsets, and PD‐L1 expression. The 9p21 deletion rate increased from pTaG2 low (9.2% homozygous, 25.8% heterozygous) to pTaG2 high (32.6%, 20.9%; p < 0.0001) but was slightly lower in pTaG3 (16.7%, 16.7%) tumors. In pT2–4 carcinomas, 23.3% homozygous and 17.9% heterozygous deletions were found, and deletions were tied to advanced pT ( p = 0.0014) and poor overall survival ( p = 0.0461). Complete MTAP loss was seen in 98.4% of homozygous deleted while only 1.6% of MTAP negative tumors had retained 9p21 copies ( p < 0.0001). MTAP loss was linked to advanced stage and poor overall survival in pT2–4 carcinomas ( p < 0.05 each). The relationship between 9p21 deletions/MTAP loss and poor patient prognosis was independent of pT and pN ( p < 0.05 each). The 9p21 deletions were associated with a noninflamed microenvironment ( p < 0.05). Complete MTAP loss is strongly tied to homozygous 9p21 deletion, aggressive disease, and noninflamed microenvironment. Drugs targeting MTAP‐deficiency may be useful in urothelial bladder carcinoma. MTAP IHC is a near perfect surrogate for MTAP deficiency in this tumor type.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsPurine-Nucleoside PhosphorylaseChromosomes, Human, Pair 9Tumor MicroenvironmentPhenotypeHomozygoteHumansMaleFemaleAgedMiddle AgedChromosome DeletionBiomarkers, TumorIn Situ Hybridization, FluorescenceTissue Array AnalysisImmunohistochemistryAdultAged, 80 and overPrognosis

Stichwörter der Autor:innen

9p21 deletionFISHMTAPimmunohistochemistrytissue microarrayurothelial bladder carcinoma

Substanzen

5'-methylthioadenosine phosphorylasePurine-Nucleoside PhosphorylaseBiomarkers, Tumor

Autor:innen und Institutionen

  • Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Urology, Charité Berlin, Berlin, Germany.
  • Institute of Pathology, Charité Berlin, Berlin, Germany.
  • Department of Pathology, Academic Hospital Fuerth, Fuerth, Germany.
  • Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Urology, Marienhospital Hamburg, Hamburg, Germany.

ORCID-Profile: Niclas C Blessin, Ronald Simon

Förderung

  • German Society of Urology
  • Deutsche Gesellschaft für Urologie

Zitieren

APA

Gorbokon, N., Wößner, N., Ahlburg, V., Plage, H., Hofbauer, S., Furlano, K., Weinberger, S., Bruch, P. G., Schallenberg, S., Roßner, F., Elezkurtaj, S., Lennartz, M., Blessin, N. C., Marx, A. H., Samtleben, H., Fisch, M., Rink, M., Slojewski, M., Kaczmarek, K., …, & Kluth, M. (2025). Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/2056-4538.70012

Vancouver

Gorbokon N, Wößner N, Ahlburg V, Plage H, Hofbauer S, Furlano K, et al. Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer. The Journal of Pathology: Clinical Research. 2025. doi:10.1002/2056-4538.70012

BibTeX
@article{Gorbokon2025,
  author = {Gorbokon, Natalia and Wößner, Niklas and Ahlburg, Viktoria and Plage, Henning and Hofbauer, Sebastian and Furlano, Kira and Weinberger, Sarah and Bruch, Paul Giacomo and Schallenberg, Simon and Roßner, Florian and Elezkurtaj, Sefer and Lennartz, Maximilian and Blessin, Niclas C and Marx, Andreas H and Samtleben, Henrik and Fisch, Margit and Rink, Michael and Slojewski, Marcin and Kaczmarek, Krystian and Ecke, Thorsten and Klatte, Tobias and Koch, Stefan and Adamini, Nico and Minner, Sarah and Simon, Ronald and Sauter, Guido and Zecha, Henrik and Horst, David and Schlomm, Thorsten and Bubendorf, Lukas and Kluth, Martina},
  title = {Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2025},
  doi = {10.1002/2056-4538.70012}
}
Kostenlos starten →